Is this email not displaying correctly? View in your browser.
Send to a colleague
HOME         ABOUT         NEWS         HOT TOPICS         TRIALS         RESOURCES         CONTACT

WCN 2021 banner


Highlights from the World Congress of Neurology 2021

Over 4400 delegates from 120 countries attended the XXV World Congress of Neurology 2021 held virtually on 3-7 October 2021 with the theme of “Inspired by the Past to build the Future of Neurology”. Our highlights include news of biomarker research to identify patients most likely to benefit from CGRP mAbs, discussions about ligand- and receptor-binding mAbs, and real-world data from different populations. Presentations on the Congress website are available on demand for up to three months:

European biomarker study seeks response indicators for CGRP mAbs

Identifying patients most likely to respond to CGRP mAbs will be key to improving access to this important group of new drugs, and a study in Italy, Germany and Spain is investigating an array of demographic, clinical, psychological, cognitive, epigenetic, pharmacogenetic, biochemical and imaging markers. “We are not expecting to see a single biomarker that will predict response, there is more likely to be a panel of markers to help us separate likely responders from non-responders,” said Professor Cristina Tassorelli, from the University of Pavia, Italy.

Read the report »
Professor Cristina Tassorelli

Ligand- and receptor-binding CGRP mAbs are equally effective

There is no difference in efficacy between ligand- and receptor-binding CGRP mAbs and there is no evidence that any one mAb works better than another, agreed speakers in response to questions at a joint session of the World Federation of Neurology and the International Headache Society. “Based on Phase 3 clinical studies, we don’t see any difference in efficacy between monoclonal antibodies that target the peptide or the receptor – they both end up inhibiting CGRP signalling,” said Professor Rami Burstein, from Harvard University, Boston, USA.

Read the report »
Professor Rami Burstein

Changing migraine patterns after erenumab and influence of personality and stress

One in three patients treated with erenumab at an Italian centre reverted from chronic to episodic migraine after one month, and 71% by the end of one year of treatment, reported Dr Gloria Vaghi, from the University of Pavia, Italy.

Read the report »
Dr Gloria Vaghi

Response to fremanezumab in Korean patients compares well with pivotal HALO studies

Reduction in migraine headache days in patients treated with fremanezumab in Korea compares well with reductions seen in the pivotal Phase 3 HALO studies in episodic and chronic migraine. Results of two phase 2b/3 studies in Korea, with the same design as the HALO trials, showed similar reductions in monthly headache days and responder rates to the international studies.

Read the report »

Rapid effects of CGRP mAbs highlighted in real world study

Nearly six out of 10 patients with chronic migraine had a significant clinical response to erenumab or galcanezumab in the first four weeks of treatment in a retrospective real world study reported from ASST Spedali Civili Brescia, Italy.

Read the report »

Fewer patients discontinue CGRP mAbs than other migraine preventives

Patients taking CGRP mAbs are less likely to discontinue treatment within 12 months than those taking other approved preventive therapies for migraine, according to US claims data from over 4,500 patients prescribed CGRP mAbs and nearly 11,000 taking other preventives.

Read the report »

For other recent news from the CGRP Forum, catch up at: News

If you’d like to contribute your experiences of using anti-CGRP therapies or share CGRP research findings, please get in touch.

Becoming a member is easy
Members have free open access simply by registering online.
Join today »
Educational Partners and Supporters (others pending)
You are receiving this email because you have subscribed to receive updates from CGRP Forum.
Should you wish to cancel your subscription, please click here to unsubscribe.